Jaguar Health in FDA Talks for Breakthrough Therapy Designation for Crofelemer in Rare Pediatric Disease
JAGX sits 19% above its 52-week low of $2.68 on elevated volume (7.5× avg).
Summary
Jaguar Health announced preliminary discussions with the FDA to evaluate Breakthrough Therapy Designation (BTD) for its drug crofelemer, targeting Microvillus Inclusion Disease (MVID). MVID is an ultrarare, lethal congenital disorder with no available therapies, and preliminary clinical data suggests crofelemer can meaningfully reduce parenteral support needs in pediatric patients. This news represents a significant positive development for Jaguar Health, which has recently been grappling with severe financial distress, including Nasdaq delisting threats and highly dilutive financing. A BTD could substantially accelerate the development and review process for crofelemer, offering a critical potential catalyst and a path to market for a drug addressing a severe unmet medical need. Traders will closely monitor further updates on the BTD application and ongoing clinical trial progress.
At the time of this announcement, JAGX was trading at $3.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $2.68 to $449.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Access Newswire.